FDA Moves to Curb Use of GLP-1 Ingredients in Unapproved Compounded Drugs
The U.S. Food and Drug Administration announced plans to restrict use of GLP-1 ingredients in compounded drugs that lack FDA approval, highlighting safety, quality and legal issues. The action follows marketing of such compounded copies by telehealth and compounding firms and coincides with a nearly 12% after-hours drop in Hims & Hers Health shares…